Description

BioMarin’s VOXZOGO Expansion Could Unlock A Powerful New Growth Wave In Rare Bone Disorders!

BioMarin Pharmaceutical Inc. reported its first quarter 2026 results highlighting a significant corporate milestone with the recent acquisition of Amicus Therapeutics. This acquisition brought two additional therapies—Galafold for Fabry disease and Pombiliti and Opfolda for Pompe disease—into BioMarin’s portfolio, expected to accelerate the company’s revenue growth trajectory. BioMarin updated its full-year 2026 revenue guidance to a range of $3.825 billion to $3.925 billion, representing approximately 20% year-over-year growth at the midpoint, while Enzyme Therapies revenue guidance was raised to $2.725 billion to $2.775 billion, reflecting a 30% growth rate fueled by the new product additions. The first quarter revenues were $766 million, up year-over-year, driven by increased patient demand for Enzyme Therapies (6% growth) and VOXZOGO, a treatment for achondroplasia. However, this growth was partially offset by order timing dynamics and lower revenue contributions from Roctavian, KUVAN, and royalties.